Laidlaw analyst Francois Brisebois downgraded NovaBay Pharmaceuticals (NYSE: NBY) from Buy to Neutral with a price target of $1.50 (from ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE